EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Saving Lives: Evaluating Naloxone Distribution in Community Drug and Alcohol Services

Anju Vivek Shivram, Frankie Anderson

BJPsych Open · 2026-06 · 12 (S1) · S263-S263

DOI: 10.1192/bjo.2026.11589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 30.06.2026. Verfasst von Anju Vivek Shivram und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This service evaluation reviewed the distribution of intramuscular and intranasal naloxone between January 2025 and January 2026 within Richmond Community Drug and Alcohol Services, as part of a harm reduction approach for people with opioid use disorder. Naloxone is a well-established opioid antagonist used to reverse opioid-related respiratory depression in emergency situations. The evaluation was particularly relevant to the London Borough of Richmond upon Thames, where drug-related deaths continue to occur despite lower prevalence overall, and where polysubstance use and exposure to potent synthetic opioids increase the risk of overdose among people accessing local services.

Methods

A retrospective review of anonymised naloxone distribution records was undertaken, capturing all kits issued over the 12-month evaluation period. Data included the total number of kits provided and the formulation supplied, either intramuscular or intranasal. Naloxone was offered in line with UK national guidance to people using opioids alone or with others, individuals who inject drugs, those assessed as being at increased risk of overdose, and people likely to witness an overdose. Distribution was supported by brief, practical harm reduction advice. This focused on using low doses and increasing gradually, especially when using a substance for the first time, allowing time for effects to be felt, and recognising that drugs may act at different speeds or vary in strength despite similar appearance. Individuals were also encouraged to inform others when using substances, access buddy or telephone support if using alone, and seek emergency medical help when concerning symptoms occurred. Findings were summarised using descriptive analysis.

Results

During the evaluation period, a total of 237 naloxone kits were distributed. Of these, 75 kits (31.6%) were intramuscular naloxone, and 162 kits (68.4 %) were intranasal naloxone. Intranasal naloxone accounted for the majority of kits provided. This reflects its ease of administration, lower risk of needlestick injury, and suitability for use by people without medical training. Distribution occurred within a population characterised by established opioid dependence, where polysubstance use and exposure to synthetic opioids were an identified risk.

Conclusion

This evaluation supports sustained naloxone distribution as an effective harm reduction measure, with intranasal naloxone facilitating wider access and rapid overdose response. Given its short duration of action, repeat dosing and urgent medical assessment remain essential, particularly with long-acting or synthetic opioids.

Zitieren

APA

Shivram, A. V., & Anderson, F. (2026). Saving Lives: Evaluating Naloxone Distribution in Community Drug and Alcohol Services. BJPsych Open, 12(S1), S263-S263. https://doi.org/10.1192/bjo.2026.11589

Vancouver

Shivram AV, Anderson F. Saving Lives: Evaluating Naloxone Distribution in Community Drug and Alcohol Services. BJPsych Open. 2026;12(S1):S263-S263. doi:10.1192/bjo.2026.11589

BibTeX
@article{Shivram2026,
  author = {Shivram, Anju Vivek and Anderson, Frankie},
  title = {Saving Lives: Evaluating Naloxone Distribution in Community Drug and Alcohol Services},
  journal = {BJPsych Open},
  year = {2026},
  volume = {12},
  number = {S1},
  pages = {S263--S263},
  doi = {10.1192/bjo.2026.11589}
}
Kostenlos starten →